keyword
MENU ▼
Read by QxMD icon Read
search

trastuzumab

keyword
https://www.readbyqxmd.com/read/29655990/inorganic-kernel-supported-asymmetric-hybrid-vesicles-for-targeting-delivery-of-stat3-decoy-oligonucleotides-to-overcome-anti-her2-therapeutic-resistance-of-bt474r
#1
Kai Shi, Yan Fang, Shan Gao, Dongjuan Yang, Hongshu Bi, Jianxiu Xue, Anqi Lu, Yuai Li, Liyuan Ke, Xiaojie Lin, Xuechao Jin, Min Li
As a recombinant humanized monoclonal antibody that targets the extracellular region of HER2 tyrosine kinase receptor, trastuzumab (TRAZ) has demonstrated comparable clinical efficacy and improved survival in patients with HER2-positive breast cancer. Nevertheless, the therapeutic potential of TRAZ is often limited due to its frequent resistance to anti-HER2 therapy. Therefore, we investigate the reversal effect of STAT3-specific decoy oligonucleotides (STAT3-decoy ODNs) on TRAZ resistance, which contain the consensus sequence within the targeted gene promoter of STAT3...
April 12, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29650929/-a-case-of-her2-positive-occult-breast-cancer-presenting-as-swollen-axillary-lymphnodes
#2
Toshiyuki Ishiba, Goshi Oda, Tsuyoshi Nakagawa, Takumi Akashi, Yamato Yamashita, Tomoki Aburatani, Taichi Ogo, Yutaka Nakashima, Hironobu Baba, Naoaki Hoshino, Yoshinobu Nishioka, Tatsuyuki Kawano
Occult breast cancer, which develops as a metastatic lesion with no primary tumor detected in the breast, is a rare breast cancer. A 68-year-old female patient particularly complained of the presence of a right axillary mass. The mass in the right axilla was palpable, but no tumor was found in both the breasts on palpation, ultrasound examination, or MRI. Partial breast resection and axillary lymph node dissection were performed following a diagnosis of invasive ductal carcinoma by core needle biopsy. There was no mammary gland tissue present around the tumor due to the pathology of the disease, and the tumor was diagnosed as occult breast cancer...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650905/-a-case-of-her2-positive-breast-cancer-with-liver-metastases-showing-three-years-of-complete-response-to-combination-therapy-with-trastuzumabplus-pertuzumab
#3
Yuri Fujimoto, Kazushige Yamaguchi, Ayako Ueno, Reo Sakurai, Yoshio Nagahisa, Shiro Imai, Kazuyuki Kawamoto
A 48-year-old woman with severe interstitial pneumonitis was diagnosed with right breast cancer(invasive ductal carcinoma, T1aN1M0, ER+, PgR-, HER2 3+)and underwent modified radical mastectomy.The patient was administered tamoxifen as adjuvant therapy.However, 1 year after the mastectomy, multiple liver metastases were found and the patient received 2 anti-HER2 agents, trastuzumab and pertuzumab.A complete response(CR)was observed with the disappearance of the liver metastases in 7 months.CR was maintained for 2 years after the initiation of treatment, and then, we started trastuzumab monotherapy, which has resulted in long-term disease control...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650843/-a-case-of-gastric-carcinoma-with-peritoneal-dissemination-treated-with-curative-resection-following-trastuzumab-plus-capecitabine-plus-cisplatin-combined-therapy
#4
Yusuke Matsuda, Satoshi Suzuki, Ritsuko Maehara, Yoshiko Matsuda, Shingo Kanaji, Masashi Yamamoto, Hiroshi Hasegawa, Koudai Yamashita, Takeru Matsuda, Taro Oshikiri, Yasuo Sumi, Tetsu Nakamura, Yoshihiro Kakeji
A 67-year-old man was referred to our hospital with a diagnosis of type 3 gastric cancer in lower third of the stomach. Computed tomography(CT)scan showed no distant metastasis, but peritoneal dissemination from gastric cancer. A laparoscopic exploration diagnosed pStage IV gastric cancer with peritoneal dissemination. Trastuzumab, capecitabine and cisplatin therapy was administered for initially unresectable gastric cancer. After 6courses of chemotherapy, primary lesion and lymph node metastasis shrank, and the peritoneal dissemination did not worsen by CT scan...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29629216/novel-systemic-therapies-for-advanced-gastric-cancer
#5
REVIEW
Hong Jun Kim, Sang Cheul Oh
Gastric cancer (GC) is the second leading cause of cancer mortality and the fourth most commonly diagnosed malignant diseases. While continued efforts have been focused on GC treatment, the introduction of trastuzumab marked the beginning of a new era of target-specific treatments. Considering the diversity of mutations in GC, satisfactory results obtained from various target-specific therapies were expected, yet most of them were unsuccessful in controlled clinical trials. There are several possible reasons underlying the failures, including the absence of patient selection depending on validated predictive biomarkers, the inappropriate combination of drugs, and tumor heterogeneity...
March 2018: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/29629076/forming-next-generation-antibody-nanoparticle-conjugates-through-the-oriented-installation-of-non-engineered-antibody-fragments
#6
Michelle K Greene, Daniel A Richards, João C F Nogueira, Katrina Campbell, Peter Smyth, Marcos Fernández, Christopher J Scott, Vijay Chudasama
The successful development of targeted nanotherapeutics is contingent upon the conjugation of therapeutic nanoparticles to target-specific ligands, with particular emphasis being placed on antibody-based ligands. Thus, new methods that enable the covalent and precise installation of targeting antibodies to nanoparticle surfaces are greatly desired, especially those which do not rely on costly and time-consuming antibody engineering techniques. Herein we present a novel method for the highly controlled and oriented covalent conjugation of non-engineered antibody F(ab) fragments to PLGA-PEG nanoparticles using disulfide-selective pyridazinedione linkers and strain-promoted alkyne-azide click chemistry...
January 7, 2018: Chemical Science
https://www.readbyqxmd.com/read/29628983/-fcrr3a-158-polymorphism-and-stromal-tumor-infiltrating-lymphocytes-and-survival-among-patients-with-metastatic-her2-positive-breast-cancer-receiving-trastuzumab-based-treatment
#7
Heejung Chae, Changhoon Yoo, Jung-A Yoon, Hee Jin Lee, Kyu-Pyo Kim, Jeong-Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Gyungyub Gong, Sung-Bae Kim
Purpose: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab. Methods: A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab-taxane combination as first-line treatment were included in this retrospective analysis...
March 2018: Journal of Breast Cancer
https://www.readbyqxmd.com/read/29628923/evaluation-of-antigen-conjugated-fluorescent-beads-to-identify-antigen-specific-b-cells
#8
Isabel Correa, Kristina M Ilieva, Silvia Crescioli, Sara Lombardi, Mariangela Figini, Anthony Cheung, James F Spicer, Andrew N J Tutt, Frank O Nestle, Panagiotis Karagiannis, Katie E Lacy, Sophia N Karagiannis
Selection of single antigen-specific B cells to identify their expressed antibodies is of considerable interest for evaluating human immune responses. Here, we present a method to identify single antibody-expressing cells using antigen-conjugated fluorescent beads. To establish this, we selected Folate Receptor alpha (FRα) as a model antigen and a mouse B cell line, expressing both the soluble and the membrane-bound forms of a human/mouse chimeric antibody (MOv18 IgG1) specific for FRα, as test antibody-expressing cells...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29627705/3d-imaging-detection-of-her2-based-in-the-use-of-novel-affibody-quantum-dots-probes-and-ratiometric-analysis
#9
Perla Pérez-Treviño, Héctor Hernández-De la Cerda, Jorge Pérez-Treviño, Oscar Raúl Fajardo-Ramírez, Noemí García, Julio Altamirano
Patients with breast cancer (BC) overexpressing HER2 (HER2+) are selected for Trastuzumab treatment, which blocks HER2 and improves cancer prognosis. However, HER2+ diagnosis, by the gold standard, immunohistochemistry, could lead to errors, associated to: a) variability in sample manipulation (thin 2D sections), b) use of subjective algorithms, and c) heterogeneity of HER2 expression within the tissue. Therefore, we explored HER2 3D detection by multiplexed imaging of Affibody-Quantum Dots conjugates (Aff-QD), ratiometric analysis (RMAFI ) and thresholding, using BC multicellular tumor spheroids (BC-MTS) (~120 μm of diameter) as 3D model of BC...
April 4, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29626535/biophysical-properties-and-heating-induced-aggregation-of-lysine-conjugated-antibody-drug-conjugates
#10
Aditya V Gandhi, Keith J Arlotta, Hsiao-Nung Chen, Shawn C Owen, John F Carpenter
The commercially available antibody-drug conjugate (ADC) product, Kadcyla® is synthesized using a two-step reaction, wherein the linker is conjugated to native lysines on the monoclonal antibody (mAb) in step 1, followed by drug conjugation to the linker-modified antibody in step 2. In our study, we synthesized a lysine conjugated ADC (Syn-ADC) on the same trastuzumab scaffold as Kadcyla® using a one-step reaction. Mass spectrometry of both products revealed a sub-population of Kadcyla® containing free linkers conjugated to the mAb, but not conjugated to the drug, which were absent in the one-step reaction ADC product...
April 4, 2018: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29626132/shortwave-infrared-fluorescence-imaging-with-the-clinically-approved-near-infrared-dye-indocyanine-green
#11
Jessica A Carr, Daniel Franke, Justin R Caram, Collin F Perkinson, Mari Saif, Vasileios Askoxylakis, Meenal Datta, Dai Fukumura, Rakesh K Jain, Moungi G Bawendi, Oliver T Bruns
Fluorescence imaging is a method of real-time molecular tracking in vivo that has enabled many clinical technologies. Imaging in the shortwave IR (SWIR; 1,000-2,000 nm) promises higher contrast, sensitivity, and penetration depths compared with conventional visible and near-IR (NIR) fluorescence imaging. However, adoption of SWIR imaging in clinical settings has been limited, partially due to the absence of US Food and Drug Administration (FDA)-approved fluorophores with peak emission in the SWIR. Here, we show that commercially available NIR dyes, including the FDA-approved contrast agent indocyanine green (ICG), exhibit optical properties suitable for in vivo SWIR fluorescence imaging...
April 6, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29626062/trastuzumab-extends-progression-free-survival-in-her2-neu-uterine-tumors
#12
(no author information available yet)
Adding trastuzumab to carboplatin-paclitaxel is well tolerated in patients with uterine serous carcinoma.
April 6, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29624378/mofi-a-software-tool-for-annotating-glycoprotein-mass-spectra-by-integrating-hybrid-data-from-the-intact-protein-and-glycopeptide-level
#13
Wolfgang Skala, Therese Wohlschlager, Stefan Senn, Gabriel E Huber, Christian G Huber
Hybrid mass spectrometry (MS) is an emerging technique for characterizing glycoproteins, which typically display pronounced microheterogeneity. Since hybrid MS combines information from different experimental levels, it crucially depends on computational methods. Here, we describe a novel software tool, MoFi, which integrates hybrid MS data to assign glycans and other post-translational modifications (PTMs) in deconvoluted mass spectra of intact proteins. Its two-stage search algorithm first assigns monosaccharide/PTM compositions to each peak and then compiles a hierarchical list of glycan combinations compatible with these compositions...
April 6, 2018: Analytical Chemistry
https://www.readbyqxmd.com/read/29621991/adjuvant-trastuzumab-duration-trials-in-her2-positive-breast-cancer-what-results-would-be-practice-changing-persephone-investigator-questionnaire-prior-to-primary-endpoint-results
#14
Louise Hiller, Janet A Dunn, Shrushma Loi, Anne-Laure Vallier, Donna L Howe, David A Cameron, David Miles, Andrew M Wardley, Helena M Earl
BACKGROUND: Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost. METHODS: A structured questionnaire asked clinicians who had recruited patients into the Persephone trial about their prior beliefs with regards to the clinical effectiveness of trastuzumab and cardiotoxicity profile, in the comparison of 6- and 12-month durations...
April 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29615305/early-stage-her2-positive-breast-cancers-not-achieving-a-pcr-from-neoadjuvant-trastuzumab-or-pertuzumab-based-regimens-have-an-immunosuppressive-phenotype
#15
Jeremy Force, Lynn J Howie, Sara E Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, Sarah L Sammons, Michelle Parks, Donna L Topping, Ryan Emerson, Gloria Broadwater, Terry Hyslop, Kimberly L Blackwell, Smita K Nair
BACKGROUND: Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2+ ) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-modulating effects. Pre- and post-treatment immune biomarkers in cancers treated with neoadjuvant TCH with or without P are lacking. In this study we quantified baseline and changes in TILs, cluster of differentiation (CD) 4+ , CD8+ , FoxP3+ , and PD-L1+ cells using immunohistochemistry (IHC) and quantified productive T-cell receptor β (TCRβ) rearrangements and TCRβ clonality using next-generation sequencing (NGS) in 30 HER2+ breast cancer tissues treated with neoadjuvant H with or without P regimens...
February 24, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29615304/corneal-changes-in-trastuzumab-emtansine-treatment
#16
Elke O Kreps, Thierry Derveaux, Hannelore Denys
No abstract text is available yet for this article.
March 12, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29615076/use-of-the-tumor-infiltrating-cd8-to-foxp3-lymphocyte-ratio-in-predicting-treatment-responses-to-combination-therapy-with-pertuzumab-trastuzumab-and-docetaxel-for-advanced-her2-positive-breast-cancer
#17
Koji Takada, Shinichiro Kashiwagi, Wataru Goto, Yuka Asano, Katsuyuki Takahashi, Tsutomu Takashima, Shuhei Tomita, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in predicting prognoses and curative effects. It is important to clarify the role of immune related gene expression in tumor-infiltrating lymphocytes in the tumor microenvironment. In this study, we evaluated the impact of chemotherapy with a TPD regimen, on immune micro environments in HER2-positive breast cancer using immune related proteins as indicators...
April 3, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29606874/trastuzumab-and-fab-fragment-modified-curcumin-peg-plga-nanoparticles-preparation-and-evaluation-in-vitro-and-in-vivo
#18
Dongyu Duan, Aiping Wang, Ling Ni, Liping Zhang, Xiuju Yan, Ying Jiang, Hongjie Mu, Zimei Wu, Kaoxiang Sun, Youxin Li
Introduction: Nanoparticles (NPs) modified with bio-ligands represent a promising strategy for active targeted drug delivery to tumour. However, many targeted ligands, such as trastuzumab (TMAB), have high molecular weight, limiting their application for targeting. In this study, we prepared Fab' (antigen-binding fragments cut from TMAB)-modified NPs (Fab'-NPs) with curcumin (Cur) as a model drug for more effective targeting of human epidermal growth factor receptor 2 (HER2/ErbB2/Neu), which is overexpressed on breast cancer cells...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29599915/pertuzumab-trastuzumab-and-eribulin-mesylate-therapy-for-previously-treated-advanced-her2-positive-breast-cancer-a-feasibility-study-with-analysis-of-biomarkers
#19
Yasutaka Tono, Mikiya Ishihara, Yoshihiro Miyahara, Satoshi Tamaru, Hiroyasu Oda, Yoshiki Yamashita, Isao Tawara, Hiroaki Ikeda, Hiroshi Shiku, Toshiro Mizuno, Naoyuki Katayama
The standard treatment for advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is the triple combination of pertuzumab, trastuzumab and docetaxel, but some patients cannot tolerate taxane. To explore a non-taxane triple therapy, we conducted a feasibility study of pertuzumab, trastuzumab and eribulin mesylate (PTE) therapy for previously treated advanced HER2-positive breast cancer with analyses of quality of life and biomarkers. Ten patients were enrolled, two of whom had a history of docetaxel allergy...
March 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29599351/analysis-of-her-family-her1-4-expression-as-a-biomarker-in-combination-therapy-with-pertuzumab-trastuzumab-and-docetaxel-for-advanced-her2-positive-breast-cancer
#20
Koji Takada, Shinichiro Kashiwagi, Wataru Goto, Yuka Asano, Tamami Morisaki, Hisakazu Fujita, Tsutomu Takashima, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: Chemotherapy with trastuzumab, pertuzumab and docetaxel (TPD regimen) is now strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER)2-positive breast cancer. In this study, we analyzed the expression of HER 1-4 proteins, and investigated whether or not their expression was predictive of the response of advanced HER2-positive breast cancer to chemotherapy with the TPD regimen. PATIENTS AND METHODS: The study consisted of 29 cases in which TPD regimen chemotherapy was carried out from September 2013 to November 2015...
April 2018: Anticancer Research
keyword
keyword
8446
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"